NSAID initiation and risk for gastrointestinal bleeding in patients receiving GLP-1 receptor agonists: A retrospective cohort study

Clicks: 1
ID: 338938
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #252 of 255 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 255 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
PURPOSE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been purported to increase risk for gastrointestinal (GI) bleeding. Our objective was to determine whether GLP-1 RAs are associated with increased risk for GI adverse events following the initiation of a nonsteroidal anti-inflammatory drug (NSAID). METHODS: This retrospective cohort study used national administrative data from the Veterans Health Administration to identify patients with type 2 diabetes who initiated an NSAID while concurrently receiving a GLP-1 RA or a comparator agent: a sodium-glucose cotransporter-2 inhibitor (SGLT-2i) or a dipeptidyl peptidase-4 inhibitor (DPP-4i). The primary outcome measure was the incidence of a GI bleed or ulcer within 12 months of NSAID initiation. Cox proportional hazards regression was used to compare risk for GI bleeding or ulcer between GLP-1 RA recipients and the comparator groups while adjusting for confounders. A sensitivity analysis was conducted using GI bleed as a secondary outcome. RESULTS: A total of 13,433 patients received a GLP-1 RA, 24,480 received an SGLT-2i, and 30,968 received a DPP-4i. The primary outcome occurred in 0.9% (n = 117) of patients receiving a concurrent GLP-1 RA, 1.0% (n = 243) of those receiving an SGLT-2i, and 1.0% (n = 308) of those receiving a DPP-4i. In adjusted regression analyses, no difference in risk for GI bleeding or ulcer was observed between GLP-1 RAs and either comparator (SGLT-2i: hazard ratio [HR], 0.85; 95% confidence interval [CI], 0.68-1.07; DPP-4i: HR, 0.82; 95% CI, 0.66- 1.01). Similar nonsignificant results were observed for the secondary outcome. CONCLUSION: We did not observe an increased risk for developing a GI bleed or ulcer within the year following NSAID initiation with concurrent GLP-1 RA therapy, relative to comparator agents.
Reference Key
openalex_W7225303346 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Elijah Miller, Matthew A. Cantrell, Brian C. Lund
Are you one of these authors? Claim your profile
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag376
URL
https://doi.org/10.1093/ajhp/zxag376
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.